151 related articles for article (PubMed ID: 30155949)
41. Intensified neoadjuvant chemoradiotherapy in locally advanced rectal cancer -- impact on long-term quality of life.
Kripp M; Wieneke J; Kienle P; Welzel G; Brade J; Horisberger K; Wenz F; Post S; Gencer D; Hofmann WK; Hofheinz RD
Eur J Surg Oncol; 2012 Jun; 38(6):472-7. PubMed ID: 22349986
[TBL] [Abstract][Full Text] [Related]
42. The effects of chemoradiotherapy on recurrence and survival in locally advanced rectal cancers with curative total mesorectal excision: a prospective, nonrandomized study.
Akgun E; Ozkok S; Tekin M; Yoldas T; Caliskan C; Kose T; Karabulut B; Sezak M; Elmas N; Ozutemiz O
World J Surg Oncol; 2017 Nov; 15(1):205. PubMed ID: 29166925
[TBL] [Abstract][Full Text] [Related]
43. Improved outcomes for rectal cancer in the era of preoperative chemoradiation and tailored mesorectal excision: a series of 338 consecutive cases.
Pacelli F; Sanchez AM; Covino M; Tortorelli AP; Bossola M; Valentini V; Gambacorta MA; Doglietto GB
Am Surg; 2013 Feb; 79(2):151-61. PubMed ID: 23336654
[TBL] [Abstract][Full Text] [Related]
44. Randomized controlled trial of 8 weeks' vs 12 weeks' interval between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer.
Terzi C; Bingul M; Arslan NC; Ozturk E; Canda AE; Isik O; Yilmazlar T; Obuz F; Birkay Gorken I; Kurt M; Unlu M; Ugras N; Kanat O; Oztop I
Colorectal Dis; 2020 Mar; 22(3):279-288. PubMed ID: 31566843
[TBL] [Abstract][Full Text] [Related]
45. Is adjuvant chemotherapy necessary for patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery in locally advanced rectal cancer? Long-term analysis of 40 ypCR patients at a single center.
Zhou J; Qiu H; Lin G; Xiao Y; Wu B; Wu W; Sun X; Lu J; Zhang G; Xu L; Liu Y
Int J Colorectal Dis; 2016 Jun; 31(6):1163-8. PubMed ID: 27044403
[TBL] [Abstract][Full Text] [Related]
46. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy.
Beddy D; Hyland JM; Winter DC; Lim C; White A; Moriarty M; Armstrong J; Fennelly D; Gibbons D; Sheahan K
Ann Surg Oncol; 2008 Dec; 15(12):3471-7. PubMed ID: 18846402
[TBL] [Abstract][Full Text] [Related]
47. Endoscopic assessment of tumor regression after preoperative chemoradiotherapy as a prognostic marker in locally advanced rectal cancer.
Sohn DK; Han KS; Kim BC; Hong CW; Chang HJ; Baek JY; Kim MJ; Park SC; Oh JH; Kim DY
Surg Oncol; 2017 Dec; 26(4):453-459. PubMed ID: 29113665
[TBL] [Abstract][Full Text] [Related]
48. Tumor response after long interval comparing 5x5Gy radiation therapy with chemoradiation therapy in rectal cancer patients.
Rombouts AJM; Hugen N; Verhoeven RHA; Elferink MAG; Poortmans PMP; Nagtegaal ID; de Wilt JHW
Eur J Surg Oncol; 2018 Jul; 44(7):1018-1024. PubMed ID: 29678303
[TBL] [Abstract][Full Text] [Related]
49. Pathologic Complete Response in Rectal Cancer: Can We Detect It? Lessons Learned From a Proposed Randomized Trial of Watch-and-Wait Treatment of Rectal Cancer.
Nahas SC; Rizkallah Nahas CS; Sparapan Marques CF; Ribeiro U; Cotti GC; Imperiale AR; Capareli FC; Chih Chen AT; Hoff PM; Cecconello I
Dis Colon Rectum; 2016 Apr; 59(4):255-63. PubMed ID: 26953983
[TBL] [Abstract][Full Text] [Related]
50. Comparative outcome between chemoradiotherapy and lateral pelvic lymph node dissection following total mesorectal excision in rectal cancer.
Kim JC; Takahashi K; Yu CS; Kim HC; Kim TW; Ryu MH; Kim JH; Mori T
Ann Surg; 2007 Nov; 246(5):754-62. PubMed ID: 17968166
[TBL] [Abstract][Full Text] [Related]
51. Pathological complete response due to a prolonged time interval between preoperative chemoradiation and surgery in locally advanced rectal cancer: analysis from the German StuDoQ|Rectalcarcinoma registry.
Lichthardt S; Wagner J; Löb S; Matthes N; Kastner C; Anger F; Germer CT; Wiegering A
BMC Cancer; 2020 Jan; 20(1):49. PubMed ID: 31959130
[TBL] [Abstract][Full Text] [Related]
52. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
[TBL] [Abstract][Full Text] [Related]
53. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
[TBL] [Abstract][Full Text] [Related]
54. Organ preservation with local excision or active surveillance following chemoradiotherapy for rectal cancer.
Creavin B; Ryan E; Martin ST; Hanly A; O'Connell PR; Sheahan K; Winter DC
Br J Cancer; 2017 Jan; 116(2):169-174. PubMed ID: 27997526
[TBL] [Abstract][Full Text] [Related]
55. Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis.
Markovina S; Youssef F; Roy A; Aggarwal S; Khwaja S; DeWees T; Tan B; Hunt S; Myerson RJ; Chang DT; Parikh PJ; Olsen JR
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):417-426. PubMed ID: 28871992
[TBL] [Abstract][Full Text] [Related]
56. Is neoadjuvant chemoradiation with dose-escalation and consolidation chemotherapy sufficient to increase surgery-free and distant metastases-free survival in baseline cT3 rectal cancer?
São Julião GP; Habr-Gama A; Vailati BB; Aguilar PB; Sabbaga J; Araújo SEA; Mattacheo A; Alexandre FA; Fernandez LM; Gomes DB; Gama-Rodrigues J; Perez RO
Eur J Surg Oncol; 2018 Jan; 44(1):93-99. PubMed ID: 29217398
[TBL] [Abstract][Full Text] [Related]
57. Nonoperative management of rectal cancer after chemoradiation opposed to resection after complete clinical response. A comparative study.
Araujo RO; Valadão M; Borges D; Linhares E; de Jesus JP; Ferreira CG; Victorino AP; Vieira FM; Albagli R
Eur J Surg Oncol; 2015 Nov; 41(11):1456-63. PubMed ID: 26362228
[TBL] [Abstract][Full Text] [Related]
58. Does residual microscopic disease after chemoradiotherapy for locally advanced rectal cancer translate into a good clinical outcome?
Geva R; Davidovics H; Soyfer S; Pelles-Avraham S; Klausner JM; Inbar M; Tulchinsky H
Colorectal Dis; 2017 Mar; 19(3):237-242. PubMed ID: 27474791
[TBL] [Abstract][Full Text] [Related]
59. Individualizing surgical treatment based on tumour response following neoadjuvant therapy in T4 primary rectal cancer.
Denost Q; Kontovounisios C; Rasheed S; Chevalier R; Brasio R; Capdepont M; Rullier E; Tekkis PP
Eur J Surg Oncol; 2017 Jan; 43(1):92-99. PubMed ID: 27717529
[TBL] [Abstract][Full Text] [Related]
60. The impact of the radiation-induced regression of positive nodes on survival in patients with rectal cancer treated with chemoradiotherapy.
Beppu N; Kakuno A; Doi H; Kamikonya N; Matsubara N; Tomita N; Yanagi H; Yamanaka N
Surgery; 2017 Feb; 161(2):422-432. PubMed ID: 27726913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
